UK Healthtech Startup Secures Europes Largest Pre-Seed Funding for Female Founders

• Level Zero Health raises $5.5m (£4.4m) in pre-seed funding, marking the largest ever secured by female founders in Europe.
• The round is led by European venture capital firm redalpine.
• Funding will accelerate Level Zero Health's mission to revolutionize hormone tracking.

UK-based startup Level Zero Health has secured $5.5m (£4.4m) in its pre-seed funding round, marking the largest amount ever raised by female founders in Europe. Led by the European venture capital firm redalpine, this funding will fuel the company’s mission to revolutionise hormone tracking. It will support the development of the world's first remote, continuous hormone monitoring device, driven by groundbreaking DNA-based sensors.

Level Zero Health was founded just over a year ago by Ula Rustamova, ex-Palantir tech lead, and Irene Jia, a medical device expert from Philips. The company’s $5.5m pre-seed funding sets a new benchmark for female-led startups in Europe. 70% of the funding comes from European investors.

The innovation is a noninvasive wearable patch that attaches to the arm and provides real-time hormone monitoring. Unlike traditional blood tests, the technology offers continuous hormone level tracking. Implications include applications in fertility treatments, menopause management, and stress monitoring.

Data-based sensors have demonstrated 98% accuracy across the human clinical range, surpassing industry standards. CEO Ula states: "Our innovative remote monitoring technology marks an enormous leap in hormone testing."

The funding will help bring the revolutionary hormone tracking solution to market, making it more accessible and insightful. Despite being in its early stages, Level Zero Health has already attracted a strong pool of potential customers.